Literature DB >> 25652468

DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma.

Rattaya Amornpisutt1, Siriporn Proungvitaya, Patcharee Jearanaikoon, Temduang Limpaiboon.   

Abstract

Cholangiocarcinoma (CCA) is a malignancy of the bile duct epithelium which is caused by liver fluke infection. The clinical symptoms of CCA were revealed as the disease progresses to advanced stage. Thus, specific diagnostic biomarkers are important for this fatal disease. We applied methylation-sensitive high-resolution melting (MS-HRM) to quantify DNA methylation levels of opioid binding protein/cell adhesion molecule-like gene (OPCML) and Secreted frizzled-related protein 1 (SFRP1) in 73 primary CCA and 10 adjacent normal tissues and evaluated the sensitivity, specificity, and accuracy of the assay. The median methylation level of OPCML in CCA was 38.7 % (ranged from 0 to 82.2 %) and of SFRP1 was 31.5 % (ranged from 0 to 86.2 %). Methylation cutoff values of OPCML and SFRP1 derived from adjacent normal tissue were 6.90 and 10.44 %, respectively. With these cutoff values, the area under curve (AUC) of OPCML was 0.932 (95 % CI 0.878-0.986) and of SFRP1 was 0.951 (95 % CI 0.905-0.996). The sensitivity, specificity, and accuracy of OPCML were 89.04, 100, and 90.36 %, respectively, and of SFRP1 were 83.56, 100, and 85.54 %, respectively. In conclusion, the DNA methylation levels of OPCML and SFRP1 could be potential biomarkers for diagnosis of CCA with high specificity, sensitivity, and accuracy, in particular for biopsy specimens. Further validation in noninvasive samples such as serum or plasma is warranted for clinical applicability, especially as early diagnostic biomarkers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25652468     DOI: 10.1007/s13277-015-3147-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.

Authors:  Sara Duarte-Pereira; Filipa Paiva; Vera Lúcia Costa; João Ramalho-Carvalho; Joana Savva-Bordalo; Angelo Rodrigues; Franclim Ricardo Ribeiro; Vitor M Silva; Jorge Oliveira; Rui Henrique; Carmen Jerónimo
Journal:  Eur J Cancer       Date:  2011-01-25       Impact factor: 9.162

2.  Methylation of secreted frizzled related protein gene in acute leukemia patients in China.

Authors:  Jian-Zhen Shen; Cheng-Bo Xu; Hai-Ying Fu; Dang-Sen Wu; Hua-Rong Zhou; Li-Ping Fan
Journal:  Asian Pac J Cancer Prev       Date:  2011

Review 3.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

Review 4.  Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?

Authors:  Stephen B Baylin; Joyce E Ohm
Journal:  Nat Rev Cancer       Date:  2006-02       Impact factor: 60.716

Review 5.  Genes and cholangiocarcinoma.

Authors:  Kanlayanee Sawanyawisuth
Journal:  Southeast Asian J Trop Med Public Health       Date:  2009-07       Impact factor: 0.267

6.  Methylated genes as new cancer biomarkers.

Authors:  M J Duffy; R Napieralski; J W M Martens; P N Span; F Spyratos; F C G J Sweep; N Brunner; J A Foekens; M Schmitt
Journal:  Eur J Cancer       Date:  2009-01-12       Impact factor: 9.162

7.  Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.

Authors:  Isabelle Renard; Steven Joniau; Ben van Cleynenbreugel; Catherine Collette; Christophe Naômé; Ilse Vlassenbroeck; Hubert Nicolas; Jean de Leval; Josef Straub; Wim Van Criekinge; Wissem Hamida; Majed Hellel; Alexandre Thomas; Laurence de Leval; Katja Bierau; David Waltregny
Journal:  Eur Urol       Date:  2009-08-05       Impact factor: 20.096

8.  Verification of complete bisulfite modification using Calponin-specific primer sets.

Authors:  Ruethairat Sriraksa; Patimaporn Chaopatchayakul; Patcharee Jearanaikoon; Chanvit Leelayuwat; Temduang Limpaiboon
Journal:  Clin Biochem       Date:  2009-11-13       Impact factor: 3.281

9.  CpG-island methylation study of liver fluke-related cholangiocarcinoma.

Authors:  R Sriraksa; C Zeller; M A El-Bahrawy; W Dai; J Daduang; P Jearanaikoon; S Chau-In; R Brown; T Limpaiboon
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

10.  OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.

Authors:  Yan Cui; Ying Ying; Andrew van Hasselt; Ka Man Ng; Jun Yu; Qian Zhang; Jie Jin; Dingxie Liu; Johng S Rhim; Sun Young Rha; Myriam Loyo; Anthony T C Chan; Gopesh Srivastava; George S W Tsao; Grant C Sellar; Joseph J Y Sung; David Sidransky; Qian Tao
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  15 in total

Review 1.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

2.  Loss of opioid binding protein/cell adhesion molecule-like gene expression in gastric cancer.

Authors:  Ning Zhang; Jide Xu; Yuhong Wang; Xuhua Heng; Liteng Yang; Xiangbin Xing
Journal:  Oncol Lett       Date:  2018-04-24       Impact factor: 2.967

3.  Matricellular proteins in cancer: a focus on secreted Frizzled-related proteins.

Authors:  Krista Marie Vincent; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2017-06-07       Impact factor: 5.782

4.  Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.

Authors:  Ricuphan Khamko; Wiphawan Wasenang; Jureerut Daduang; Chatri Settasatian; Temduang Limpaiboon
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

5.  Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.

Authors:  Bin Lian; Hong Li; Yaobang Liu; Dahai Chai; Yali Gao; Yangyang Zhang; Jia Zhou; Jinping Li
Journal:  Breast Cancer       Date:  2020-10-27       Impact factor: 4.239

6.  OPCML Exerts Antitumor Effects in Cholangiocarcinoma via AXL/STAT3 Inactivation and Rho GTPase Down-regulation.

Authors:  Ricuphan Khamko; Jureerut Daduang; Chatri Settasatian; Temduang Limpaiboon
Journal:  Cancer Genomics Proteomics       Date:  2021 Nov-Dec       Impact factor: 4.069

7.  Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract.

Authors:  V Branchi; P Schaefer; D Dietrich; H Matthaei; A Semaan; A Kania; P Lingohr; J C Kalff; N Schäfer; G Kristiansen
Journal:  Clin Epigenetics       Date:  2016-12-12       Impact factor: 6.551

8.  Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.

Authors:  Shunlin Liu; Xiaoying Chen; Ruhua Chen; Jinzhi Wang; Guoliang Zhu; Jianzhong Jiang; Hongwei Wang; Shiwei Duan; Jianan Huang
Journal:  Oncotarget       Date:  2017-05-30

9.  A DNA-Methylated Sight on Autoimmune Inflammation Network across RA, pSS, and SLE.

Authors:  Xingqiang Wang; Dongyun Lei; Jie Ding; Shuang Liu; Li Tao; Fan Zhang; Jiangyun Peng; Jian Xu
Journal:  J Immunol Res       Date:  2018-08-12       Impact factor: 4.818

Review 10.  Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment.

Authors:  Keishi Yamashita; Kei Hosoda; Nobuyuki Nishizawa; Hiroshi Katoh; Masahiko Watanabe
Journal:  Cancer Sci       Date:  2018-10-26       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.